Duopharma Biotech signs agreement to supply Sputnik V to Malaysia


Duopharma Biotech Berhad, one of Malaysia’s leading pharmaceutical companies, has signed an agreement with the government to supply Malaysia with 6.4 million doses of the Russian anti-COVID19 vaccine Sputnik V. This was reported in a press release of the company. The delivery of the vaccine depends on the fulfilment of the conditions of the preliminary supply arrangements, including the approval of the vaccine by the Drug Control Authority of Malaysia. According to a publication in The Lancet, one of the most respected medical journals in the world, the effectiveness of the Sputnik V vaccine against coronavirus was 91.6%. In addition, it is one of three vaccines in the world to have efficiency rating of more than 90%, there were also no serious side effects associated with the vaccine, the press release noted. The Sputnik V vaccine has been successfully registered in 66 countries. The three countries that registered Sputnik V – Hungary, Slovakia and Argentina – are members of PIC/S. According to the RDIF, to date, 20 million people around the world have received the vaccine.


WordPress Ads
Exit mobile version